FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS

T-FITNESS aims to enhance T cell therapy by preventing exhaustion through miRNA-based circuits and CRISPR/Cas editing, improving treatment efficacy for solid tumors in cancer patients.

Subsidie
€ 4.387.825
2022

Projectdetails

Introduction

Cell and gene therapies offer a massive paradigm shift from current treatment options and hold the potential to cure previously untreatable diseases. Naturally-occurring and genetically modified T cells with chimeric antigen (CAR) or T cell receptors (TCR) have demonstrated remarkable curative capacities against advanced hematologic malignancies but have shown limited efficacy in treating solid tumors.

Challenges in T Cell Therapy

Major barriers hindering the full antitumor potential of T cells are:

  • The immunosuppressive signals within the tumor microenvironment
  • Persisting antigenic stimuli that push T cells into a highly dysfunctional state called “exhaustion”

Proposed Solution: T-FITNESS

Herein, we propose a groundbreaking technology, T-FITNESS, which will enable antitumor T cells to become refractory to exhaustion.

Core Technology

At the core of the platform are microRNA (miRNA)-based synthetic logic circuits capable of rewiring the transcriptional networks orchestrating T cell exhaustion.

Integration with CRISPR/Cas

By harnessing the power of CRISPR/Cas genome editing, we will integrate sensors of miRNAs upregulated in exhausted cells into untranslated regions of one or more transcription factors driving T cell exhaustion, to enable their fine-tuned downregulation.

Validation and Development

We will validate the reprogramming efficacy of T-FITNESS by performing extensive functional analyses:

  1. In vitro
  2. In vivo

We will advance the best circuits towards the clinic by developing an automated cGMP-compliant manufacturing process for point-of-care production of T-FITNESS-edited CAR-T cells.

Collaborative Effort

To develop this innovative platform, we will bring together a multidisciplinary consortium of academic and industry partners that combine their unique expertise in:

  • T cell therapy and immunology
  • Synthetic biology
  • Genome editing
  • cGMP manufacturing
  • Bioinformatics
  • Communication

Impact on Cancer Treatment

Easily integrable within CAR-T, TCR-T, and tumor-infiltrating lymphocyte (TIL) platforms, T-FITNESS will unleash the curative potential of T cell therapy for the benefit of an ever-growing number of cancer patients.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 4.387.825
Totale projectbegroting€ 4.387.825

Tijdlijn

Startdatum1-9-2022
Einddatum31-8-2026
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • STIFTUNG LEIBNIZ-INSTITUT FUR IMMUNTHERAPIEpenvoerder
  • FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
  • FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
  • MILTENYI BIOTEC BV & CO KG
  • INNOVATION ACTA SRL
  • KEMIJSKI INSTITUT
  • EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Land(en)

GermanySpainFranceItalySloveniaSwitzerland

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"

The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.

€ 2.996.550
EIC Pathfinder

Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.

The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.

€ 2.744.300
EIC Pathfinder

Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures

Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.

€ 2.552.277
EIC Pathfinder

Emerging technologies for crystal-based gamma-ray light sources

TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.

€ 2.643.187

Vergelijkbare projecten uit andere regelingen

ERC STG

Polyclonal anti-tumor immunity by engineered human T cells

This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.

€ 1.812.500
ERC POC

Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid Tumors

CAR-T(uning) aims to enhance CAR-T therapy for NSCLC by improving treatment persistence and reducing tumor immunosuppression, paving the way for effective, broadly applicable cancer therapies.

€ 150.000
ERC ADG

Reversing T cell dysfunction in cancer by multimodal genetic screening

This project aims to validate and characterize genes reversing T cell dysfunction in vivo to enhance immunotherapy effectiveness against cancer.

€ 2.499.375
ERC STG

Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment

The CAR-TIME project aims to map the tumor immune microenvironment in lymphoma to enhance CAR T cell therapy efficacy and identify predictive biomarkers for patient response.

€ 1.499.875